Q
QuantAbundanceAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

30,438 signal articles · 135 in last 24h · 154,019 total before filter · latest 57m ago
135last 24h
869last 7d
144● bullish (7d)
99● bearish (7d)
214publishers
AllMacro207Earnings105M&A125Regulatory22Product21Analyst16
✕ clear all filtersticker: PFESentiment:bullishneutralbearish✓ showing all (incl. clickbait)
How Investors Are Reacting To Pfizer (PFE) Easing Policy Pressures And New HHS Revenue-Sharing Deal
Simply Wall St.3d agoneutral
How Investors Are Reacting To Pfizer (PFE) Easing Policy Pressures And New HHS Revenue-Sharing Deal

Earlier this month, Pfizer’s CEO Albert Bourla told investors at Morgan Stanley’s Global Healthcare Conference that major headwinds such as tariffs, drug-pricing pressures, declining COVID-19 sales and upcoming patent expiries are beginning to ease, supported by cost actions and a growing mix of newer therapies. At the same time, Pfizer’s agreement to share a portion of any additional overseas pricing revenue with the U.S. Department of Health and Human Services, alongside management’s...

PFE
3 AI Stocks To Watch With Up To 45% Earnings Growth
Simply Wall St.22d agoneutral
3 AI Stocks To Watch With Up To 45% Earnings Growth

With central banks lifting interest rates to tackle inflation, investors are hunting for themes that do not rely purely on cheap money to grow. Artificial intelligence in healthcare is one such story. It focuses on software and data rather than heavy assets. This article highlights three Transformative AI Healthcare Stocks from our screener that apply algorithms to diagnostics, treatment decisions, and hospital efficiency. The three stocks that follow are only a starting sample from this...

PFETEM
Pfizer (PFE) Reaches Confidential Settlement In Depo Provera Litigation
Simply Wall St.24d agoneutral
Pfizer (PFE) Reaches Confidential Settlement In Depo Provera Litigation

Pfizer (NYSE:PFE) has reached a confidential settlement covering federal lawsuits over its Depo-Provera contraceptive and alleged intracranial meningioma risk. The agreement reportedly addresses more than 6,000 cases, with financial terms not disclosed and no admission of liability by Pfizer. The resolution closes a multi year legal overhang tied to Depo-Provera and brings clarity to a significant product liability dispute. This kind of large scale legal settlement can shift how investors...

PFE
Jobs Numbers, SpaceX Earnings: What to Watch This Week
The Wall Street Journal52d agoneutral
Jobs Numbers, SpaceX Earnings: What to Watch This Week

The monthly jobs report comes out Friday. Before that, Elon Musk’s SpaceX will post its first earnings report as a listed company. Also reporting: Walt Disney; tech companies Palantir and Advanced Micro Devices; ride-sharing firms Uber and Lyft; private-equity firms Apollo, Carlyle and TPG; and fast-food chains McDonald's and Wendy’s.

AMDAMGNCATFANGGILDLYFTMCDMPC+8
Bloomberg64d agoneutral
Trump Takes Another Swing at Drug Industry in Made-in-USA Push

(Bloomberg) -- President Donald Trump’s threat of 100% tariffs against generic medicines is a major expansion of a strategy he’s been using against the pharmaceutical industry since his second term began. Most Read from BloombergTrump’s 100% Generic Drug Duty Threatens US Low-Cost SupplyApple to Launch ‘Upgrade’ Device Leasing Program With Klarna to Spur SalesTrump Extends Pardons to Companies, Echoing a 17th Century KingSpaceX Set to Unlock $116 Billion in Shares After IPO Restrictions LiftKrem

PFE
Pfizer (PFE) Dismissed From Generic Drug Price Fixing Lawsuit
Simply Wall St.89d agobearish
Pfizer (PFE) Dismissed From Generic Drug Price Fixing Lawsuit

Pfizer (NYSE:PFE) has been dismissed as a defendant in a major federal lawsuit alleging generic drug price fixing. The court found there was not enough evidence to support claims of Pfizer's involvement in alleged collusion. The dismissal removes a legal overhang tied to long running litigation involving multiple generic drugmakers. Pfizer is a large global pharmaceutical company with a portfolio spanning prescription medicines, vaccines, and other healthcare products. For investors...

PFE
Big pharma taps UK playbook to pressure Europe on drug prices
Reuters Videos99d agoneutralVIDEO
Big pharma taps UK playbook to pressure Europe on drug prices

<body><p>STORY: Big pharma is receiving pushback from European capitals on drug pricing.&nbsp;</p><p>So they’re turning to a playbook that brought them success in the UK.</p><p>Making threats to pull investment plans to pressure policymakers.&nbsp;</p><p>The industry notched a win when the British government agreed to increase medicine spending as part of a broader deal to avoid U.S.-imposed tariffs.&nbsp;</p><p>The latest nation to face pressure is Germany, which has been debating legislation to tighten spending on medicines.&nbsp;</p><p>A Reuters European Pharma correspondent Maggie Fick said pressure in the last week has ramped up.&nbsp;</p><p>"The CEO of Pfizer wrote a letter to the German chancellor warning that their future investments in the country may be at risk over these proposed changes to pricing laws."</p><p>Meanwhile, AstraZeneca warned that it may not launch new medicines in Germany if these changes go ahead.</p><p>Earlier in June, Eli Lilly announced it would halve a planned $2.7 billion investment, also citing the proposed legislation.&nbsp;</p><p>This bid to cap costs has centered Germany in a broader tussle between drugmakers and European governments that began several months ago.</p><p>That tension has been sharpened by the impact on Europe of U.S. President Donald Trump's pricing push.</p><p>This aims to tie prescription medicine prices in the lucrative U.S. market to ​lower prices elsewhere, including in Europe.</p><p>Major drugmakers have struck deals with the White House to lower drug costs in exchange for tariff exemptions, adding to pressure for increasing prices elsewhere.</p></body>

LLYPFE
Scott Melker explains why the Fed was secretly designed for banks
Yahoo Finance Video125d agoneutralVIDEO
Scott Melker explains why the Fed was secretly designed for banks

Scott Melker discusses the history and structure of the Federal Reserve and presents bitcoin as a decentralized alternative. “The Daily Wolf with Scott Melker” airs on Yahoo Finance every day at 12:00 p.m. Tune in for your daily dose of all things crypto.Make sure to also check out Yahoo Finance's new crypto hub to find the latest crypto-related news.

PFE
Rate Cuts Are Off the Table. Here Are 2 Stocks Under $30 Built Exactly for This Moment
24/7 Wall St.128d agobearish
Rate Cuts Are Off the Table. Here Are 2 Stocks Under $30 Built Exactly for This Moment

With short-term rates still elevated, tariff uncertainty churning through earnings models, and credit spreads widening at the margins, balance sheet quality has quietly become the most underrated factor in equity selection. Stocks under $30 often get dismissed as broken or speculative, but a handful of large, cash-generative businesses currently trade in that zone with the ... Rate Cuts Are Off the Table. Here Are 2 Stocks Under $30 Built Exactly for This Moment

NUPFE
Michael Burry’s Latest Buys Include a 6.66% Yielding Pharma Giant and an Oil Stock Up 46% This Year. Here Is Why
24/7 Wall St.132d agobullish
Michael Burry’s Latest Buys Include a 6.66% Yielding Pharma Giant and an Oil Stock Up 46% This Year. Here Is Why

Pfizer (NYSE:PFE) at $25.75, Molina Healthcare (NYSE:MOH) at $186.80, and Halliburton (NYSE:HAL) at $41.29 trade at defensive, cash-generative valuations. Michael Burry purchased these shares for their real earnings and margin stability, and with inflation still pressuring margins across the market, names that generate cash, hold pricing power, and trade at sober multiples carry a structural ... Michael Burry’s Latest Buys Include a 6.66% Yielding Pharma Giant and an Oil Stock Up 46% This Year.

HALMOHPFE
AMD and Pfizer earnings, job openings, Fedspeak: What to Watch
Yahoo Finance Video143d agoneutralVIDEO
AMD and Pfizer earnings, job openings, Fedspeak: What to Watch

Asking for a Trend Host Josh Lipton previews several of the biggest stories to come tomorrow,&nbsp;Tuesday, May 5, including earnings results from Advanced Micro Devices (AMD), Pfizer (PFE), and Anheuser-Busch Inbev (BUD); fresh labor data in the form of the latest Job Openings and Labor Turnover Survey (JOLTS) report; and commentary from Federal Reserve Vice Chair for Supervision Michelle Bowman and Governor Michael Barr.

AMDPFE
Jobs Report, Tech Earnings: What to Watch This Week
The Wall Street Journal143d agoneutral
Jobs Report, Tech Earnings: What to Watch This Week

Investors won’t get too much of a respite from a big week trading the AI boom, with Palantir, Advanced Micro Devices, and CoreWeave reporting earnings. A bevy of data about the U.S. jobs market will also be watched closely, culminating in April nonfarm payroll numbers Friday.

AMDCRWVDUOLPFEPLTRPYPLSHOP